Astellas Pharma (OTCMKTS:ALPMY) Releases Earnings Results, Beats Estimates By $0.27 EPS

Astellas Pharma (OTCMKTS:ALPMY) posted its quarterly earnings results on Wednesday. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.27, Zacks reports. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%.

Astellas Pharma Stock Up 2.2%

OTCMKTS ALPMY traded up $0.30 on Wednesday, reaching $14.11. The company had a trading volume of 34,902 shares, compared to its average volume of 169,851. The stock has a market capitalization of $25.53 billion, a P/E ratio of 13.13 and a beta of 0.08. The company’s fifty day moving average is $13.41 and its 200 day moving average is $14.63. Astellas Pharma has a 52-week low of $10.03 and a 52-week high of $17.35. The company has a quick ratio of 0.90, a current ratio of 1.17 and a debt-to-equity ratio of 0.17.

Analyst Ratings Changes

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).